Serum lipid profile and plasma fatty acid composition in hemodialysis patients - Comparison with chronic kidney disease patients

In Vivo

Volumn 22, Issue 5, 2008, Pages 609-612

  Nakamura, Norio ^a   Fujita, Takeshi ^a   Kumasaka, Ryuichiro ^a   Murakami, Reiichi ^a   Shimada, Michiko ^a   Shimaya, Yuko ^a   Osawa, Hiroshi ^a   Yamabe, Hideaki ^a   Okumura, Ken ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Chronic kidney disease (CKD); Fatty acid composition; Hemodialysis; Polyunsaturated fatty acids (PUFA)

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LINOLEIC ACID; LIPOPROTEIN A; POLYUNSATURATED FATTY ACID; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FATTY ACID ANALYSIS; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPID METABOLISM; MALE;

EID: 53849147603     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F and Laniere N; European Uremic Toxin Working Group: Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 20: 1048-1056, 2005.
2. Kasiske BL: Hyperlipidemia in patients with chronic kidney disease. Am J Kidney Dis 32(Suppl 3): S142-S156, 1998.
3. Dyerberg J: Linoleate-derived polyunsaturated fatty acids and prevention of atherosclerosis. Nutr Rev 44: 125-134, 1986.
4. Peck LW, Monsen ER and Ahmad S: Effect of three sources of long-chain fatty acids on the plasma fatty acid profile, plasma prostaglandin E2 concentrations, and pruritus symptoms in hemodialysis. Am J Clin Nutr 64: 210-214, 1996.
5. Koorts AM, Viljoen M and Kruger MC: Red blood cell fatty acid profile of chronic renal failure patients receiving maintenance haemodialysis treatment. Prostaglandins Leukot Essent Fatty Acids 67: 13-18, 2002.
6. Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, Ura N, Kiyohara Y, Hirakata H, Moriyama T, Ando Y, Nitta K, Inaguma T, Narita I, Iso H, Wakai K, Yasuda Y, Tsukmoto Y, Ito S, Makino H, Hishida A and Matsuo S: Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol 11: 156-163, 2007.
7. Nakamura N, Kumasaka R, Osawa H, Yamabe H, Shirato K, Fujita T, Murakami R, Shimada M, Nakamura M, Okumura K, Hamazaki K and Hamazaki T: Effects of eicosapentaenoic acids on oxidative stress and plasma fatty acid composition in patients with lupus nephritis. In Vivo 19: 879-882, 2005.
8. Nakamura N, Hamazaki T, Yamazaki K, Taki H, Kobayashi M, Yazawa K and Ibuki F: Intravenous infusion of tridocosahexaenoyl-glycerol emulsion into rabbits: effects on leukotriene B4/5 production and fatty acid composition of plasma and leukocytes. J Clin Invest 92: 1253-1261, 1993.
9. Folch J, Lees M and Sloane-Stanley GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226: 47-509, 1957.
10. Pecoits-Filho R, Lindholm B and Stenvinkel P: The malnutrition, inflammation, and atherosclerosis (MIA) syndrome - the heart of the matter. Nephrol Dial Transplant 17(Suppl 11): 28-31, 2002.
11. Brenner RR: Hormonal modulation of delta 6 and delta 5 desaturase: case of diabetes. Prostaglandins Leukot Essent Fatty Acids 68: 151-162, 2003.
12. Nakamura N, Hamazaki T, Kobayashi M and Yazawa K: The effect of oral administration of eicosapentaenoic and docosahexaenoic acids on acute inflammation and fatty acid composition in rats. J Nutr Sci Vitaminol 40: 161-170, 1994.